1. Maintenance therapy with adalimumab (ADA) was associated with more frequent objective improvement based on Magnetic Resonance Enterography (MRE) findings than immunomodulator (IM) in pediatric ...
1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with HR 0.45 (significant). 2. HR for progression-free survival (HR 0.76) and overall survival (HR ...